Steri, Veronica

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer

Cited by 820

Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins

Pance, K., Gramespacher, J. A., Byrnes, J. R., Salangsang, F., Serrano, J.-A. C., Cotton, A. D., Steri, V., & Wells, J. A. (2023) · Nature Biotechnology

Protein Degradation and InhibitorsMonoclonal and Polyclonal Antibodies Research

Cited by 265

KRAS G12C inhibition produces a driver-limited state revealing collateral dependencies

Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling

Protein Kinase Regulation and GTPase SignalingCancer Genomics and Diagnostics

Cited by 175

A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy

Zhang, Z., Rohweder, P. J., Ongpipattanakul, C., Basu, K., Bohn, M.-F., Dugan, E. J., Steri, V., Hann, B., Shokat, K. M., & Craik, C. S. (2022) · Cancer Cell

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 136

Surface Proteomics Reveals CD72 as a Target for In Vitro –Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1 -Rearranged B-ALL

Nix, M. A., Mandal, K., Geng, H., Paranjape, N., Lin, Y.-H. T., Rivera, J. M., Marcoulis, M., White, K. L., Whitman, J. D., Bapat, S. P., et al. (2021) · Cancer Discovery

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 72